Novartis Strengthens Cardiovascular Pipeline with $925M Acquisition of Anthos Therapeutics Acquisition

Boston, MA, and Basel, Switzerland, February 11, 2025 (Novartis) -- Novartis has announced a definitive agreement to acquire Anthos Therapeutics, a Boston-based biopharmaceutical company, for $925 million, strengthening its cardiovascular portfolio. The acquisition adds abelacimab, a late-stage monoclonal antibody targeting Factor XI inhibition, which has demonstrated significant reductions in bleeding events in clinical trials. Expected to close in the first half of 2025, this transaction aligns with Novartis' strategy to advance innovative therapies for cardiovascular disease.

Read full article here.